MAPT and Alzheimer disease: Tarawneh et al. (2015) studied the usefulness of various CSF markers (e.g., Aβ42, p-tau) in predicting rates of whole-brain neurodegeneration and whole-brain atrophy in 23 subjects with mild AD and 64 cognitively normal-aged control subjects from The Charles F. and Joanne Knight Alzheimer’s Disease Research Center at Washington University School of Medicine (Table 1).